Suppr超能文献

亚铁螯合肽激动剂作为治疗工具。

Hepcidin agonists as therapeutic tools.

机构信息

Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; and.

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

出版信息

Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9.

Abstract

Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.

摘要

亚铁整合素激动剂是一类新的化合物,可调节血液中铁的水平,限制铁的吸收,并可能改善血色病、β-地中海贫血、真性红细胞增多症和其他铁稳态失调导致或促成疾病的疾病的治疗。亚铁整合素激动剂还有可能预防铁过载或慢性肝病患者中噬铁菌感染的严重并发症。本综述强调了支持开发亚铁整合素激动剂治疗这些疾病的临床前研究。

相似文献

1
Hepcidin agonists as therapeutic tools.
Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9.
2
New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.
Haematologica. 2019 Sep;104(9):1768-1781. doi: 10.3324/haematol.2018.209874. Epub 2019 Feb 21.
3
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
Blood. 2016 Jul 14;128(2):265-76. doi: 10.1182/blood-2015-10-676742. Epub 2016 May 6.
5
Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Haematologica. 2007 May;92(5):583-8. doi: 10.3324/haematol.10842.
6
Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Hematol Oncol Clin North Am. 2014 Apr;28(2):387-401. doi: 10.1016/j.hoc.2013.11.004. Epub 2014 Jan 18.
7
Hepcidin biology and therapeutic applications.
Expert Rev Hematol. 2010 Apr;3(2):153-5. doi: 10.1586/ehm.10.1.
8
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
J Clin Invest. 2010 Dec;120(12):4466-77. doi: 10.1172/JCI41717. Epub 2010 Nov 22.
9
The pathophysiology and pharmacology of hepcidin.
Trends Pharmacol Sci. 2014 Mar;35(3):155-61. doi: 10.1016/j.tips.2014.01.004. Epub 2014 Feb 17.

引用本文的文献

2
Polycythaemia vera.
Nat Rev Dis Primers. 2025 Apr 17;11(1):26. doi: 10.1038/s41572-025-00608-3.
3
Hepcidin mediates the disorder of iron homeostasis and mitochondrial function in mice under hypobaric hypoxia exposure.
Apoptosis. 2025 Apr;30(3-4):1076-1091. doi: 10.1007/s10495-025-02079-z. Epub 2025 Feb 22.
4
Cardiac injury caused by iron overload in thalassemia.
Front Pediatr. 2025 Jan 27;13:1514722. doi: 10.3389/fped.2025.1514722. eCollection 2025.
5
Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer.
Cancers (Basel). 2024 Dec 5;16(23):4068. doi: 10.3390/cancers16234068.
8
Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives.
Front Immunol. 2024 Aug 5;15:1403458. doi: 10.3389/fimmu.2024.1403458. eCollection 2024.
10
A Review of New Concepts in Iron Overload.
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):98-107.

本文引用的文献

1
What can we learn from ineffective erythropoiesis in thalassemia?
Blood Rev. 2018 Mar;32(2):130-143. doi: 10.1016/j.blre.2017.10.001. Epub 2017 Oct 3.
2
Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.
Blood. 2017 Jul 20;130(3):245-257. doi: 10.1182/blood-2017-03-772715. Epub 2017 May 2.
3
Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia.
JCI Insight. 2017 Mar 23;2(6):e92002. doi: 10.1172/jci.insight.92002.
4
Targeting iron metabolism in drug discovery and delivery.
Nat Rev Drug Discov. 2017 Jun;16(6):400-423. doi: 10.1038/nrd.2016.248. Epub 2017 Feb 3.
5
A Red Carpet for Iron Metabolism.
Cell. 2017 Jan 26;168(3):344-361. doi: 10.1016/j.cell.2016.12.034.
6
Pharmacological Targeting of the Hepcidin/Ferroportin Axis.
Front Pharmacol. 2016 Jun 21;7:160. doi: 10.3389/fphar.2016.00160. eCollection 2016.
7
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
Blood. 2016 Jul 14;128(2):265-76. doi: 10.1182/blood-2015-10-676742. Epub 2016 May 6.
8
Haemochromatosis.
Lancet. 2016 Aug 13;388(10045):706-16. doi: 10.1016/S0140-6736(15)01315-X. Epub 2016 Mar 12.
9
New strategies to target iron metabolism for the treatment of beta thalassemia.
Ann N Y Acad Sci. 2016 Mar;1368(1):162-8. doi: 10.1111/nyas.13018. Epub 2016 Feb 25.
10
Hepcidin regulation in the anemia of inflammation.
Curr Opin Hematol. 2016 May;23(3):189-97. doi: 10.1097/MOH.0000000000000236.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验